Iradimed (IRMD) and Its Competitors Financial Review

Iradimed (NASDAQ: IRMD) is one of 104 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Iradimed to similar companies based on the strength of its analyst recommendations, dividends, earnings, valuation, institutional ownership, profitability and risk.


How to Become a New Pot Stock Millionaire

This table compares Iradimed and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iradimed 2.17% 3.03% 2.58%
Iradimed Competitors -62.26% -47.35% -18.28%

Valuation and Earnings

This table compares Iradimed and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Iradimed $23.08 million $490,000.00 183.13
Iradimed Competitors $1.54 billion $111.80 million -143.37

Iradimed’s peers have higher revenue and earnings than Iradimed. Iradimed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

16.3% of Iradimed shares are held by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 60.1% of Iradimed shares are held by insiders. Comparatively, 15.7% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Iradimed has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Iradimed’s peers have a beta of 0.80, suggesting that their average stock price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Iradimed and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iradimed 0 0 2 0 3.00
Iradimed Competitors 493 1873 3736 112 2.56

Iradimed presently has a consensus target price of $17.50, suggesting a potential upside of 19.45%. As a group, “Surgical & medical instruments” companies have a potential upside of 12.70%. Given Iradimed’s stronger consensus rating and higher possible upside, research analysts plainly believe Iradimed is more favorable than its peers.


Iradimed beats its peers on 9 of the 13 factors compared.

About Iradimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with's FREE daily email newsletter.

Leave a Reply